Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.
Solid Tumor
DRUG: GLS-012|DRUG: GLS-010
Number of Participants with a Dose-Limiting Toxicity (DLT) and MTD in the dose escalation stage, Up to 21 days after the first dose|Number of participants with treatment-related adverse events of GLS-012 monotherapy and in combination with GLS-010 in the expansion stage as assessed by CTCAE V5.0, Up to approximately 24 months
Maximum plasma concentration (Cmax) of GLS-012 monotherapy and in combination with GLS-010, Up to approximately 4.5 months|Elimination half-life (T1/2) of GLS-012 monotherapy and in combination with GLS-010, Up to approximately 4.5 months|Objective response rate (ORR), Up to approximately 24 months|Disease control rate (DCR), Up to approximately 24 months|Preliminary anti-tumor activity: Duration of response (DOR), time to response (TTR), progression free survival (PFS), overall survival (OS), Up to approximately 24 months|Duration of response (DOR), Up to approximately 24 months|Time to response (TTR), Up to approximately 24 months|Progression free survival (PFS), Up to approximately 24 months|Overall survival (OS), Up to approximately 24 months
Receptor occupancy (RO) of GLS-012 in the dose escalation stage of GLS-012 monotherapy, Up to approximately 4.5 months
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.